162 related articles for article (PubMed ID: 38546414)
21. Distinct features of hypereosinophilic syndrome with neuropathy from eosinophilic granulomatosis with polyangiitis.
Takeuchi H; Kawamura K; Kawasaki T; Oka N
Front Neurol; 2022; 13():1057767. PubMed ID: 36457867
[TBL] [Abstract][Full Text] [Related]
22. A rare case report of polyangiitis overlap syndrome: granulomatosis with polyangiitis and eosinophilic granulomatosis with polyangiitis.
Quan MV; Frankel SK; Maleki-Fischbach M; Tan LD
BMC Pulm Med; 2018 Nov; 18(1):181. PubMed ID: 30497438
[TBL] [Abstract][Full Text] [Related]
23. Experimental Modeling of Eosinophil-Associated Diseases.
Upparahalli Venkateshaiah S; Manohar M; Kandikattu HK; Mishra A
Methods Mol Biol; 2021; 2241():275-291. PubMed ID: 33486743
[TBL] [Abstract][Full Text] [Related]
24. Biological Modulators in Eosinophilic Diseases.
Sriaroon P; Ballow M
Clin Rev Allergy Immunol; 2016 Apr; 50(2):252-72. PubMed ID: 25129490
[TBL] [Abstract][Full Text] [Related]
25. Eosinophilic Granulomatosis With Polyangiitis: Dissecting the Pathophysiology.
Fagni F; Bello F; Emmi G
Front Med (Lausanne); 2021; 8():627776. PubMed ID: 33718405
[TBL] [Abstract][Full Text] [Related]
26. Eosinophils and eosinophilic immune dysfunction in health and disease.
Jackson DJ; Akuthota P; Roufosse F
Eur Respir Rev; 2022 Mar; 31(163):. PubMed ID: 35082127
[TBL] [Abstract][Full Text] [Related]
27. Targeted Anti-IL-5 Therapies and Future Therapeutics for Hypereosinophilic Syndrome and Rare Eosinophilic Conditions.
Harish A; Schwartz SA
Clin Rev Allergy Immunol; 2020 Oct; 59(2):231-247. PubMed ID: 31919743
[TBL] [Abstract][Full Text] [Related]
28. Biologics for the Treatment of Allergic Conditions: Eosinophil Disorders.
Olivieri B; Tinazzi E; Caminati M; Lunardi C
Immunol Allergy Clin North Am; 2020 Nov; 40(4):649-665. PubMed ID: 33012326
[TBL] [Abstract][Full Text] [Related]
29. Safety of dupilumab in T2 airways conditions: focus on eosinophilia across trials and real-life evidence.
Caminati M; Micheletto C; Norelli F; Olivieri B; Ottaviano G; Padoan R; Piacentini G; Schiappoli M; Senna G; Menzella F
Expert Opin Biol Ther; 2024; 24(1-2):15-23. PubMed ID: 38197326
[TBL] [Abstract][Full Text] [Related]
30. Targeted Molecular Therapies in Allergy and Rhinology.
Damask CC; Ryan MW; Casale TB; Castro M; Franzese CB; Lee SE; Levy JM; Lin SY; Lio PA; Peters AT; Platt MP; White AA
Otolaryngol Head Neck Surg; 2021 Jan; 164(1_suppl):S1-S21. PubMed ID: 33138725
[TBL] [Abstract][Full Text] [Related]
31. Eosinophilic Granulomatosis with Polyangiitis: Clinical Pathology Conference and Review.
Wu EY; Hernandez ML; Jennette JC; Falk RJ
J Allergy Clin Immunol Pract; 2018; 6(5):1496-1504. PubMed ID: 30197069
[TBL] [Abstract][Full Text] [Related]
32. Urine eosinophil-derived neurotoxin: A potential marker of activity in select eosinophilic disorders.
Makiya MA; Khoury P; Kuang FL; Mata AD; Mahmood S; Bowman A; Espinoza D; Kovacs N; Brown T; Holland N; Wetzler L; Ware JM; Dyer AM; Akuthota P; Bochner BS; Chinchilli VM; Gleich GJ; Langford C; Merkel PA; Specks U; Weller PF; Wechsler ME; Prussin C; Fay MP; Klion AD
Allergy; 2023 Jan; 78(1):258-269. PubMed ID: 35971862
[TBL] [Abstract][Full Text] [Related]
33. Eosinophilic granulomatosis with polyangitis: A new target for biologicals.
Bayrak Durmaz MS; Çelebi Sözener Z; Bavbek S
Tuberk Toraks; 2022 Mar; 70(1):93-101. PubMed ID: 35362309
[TBL] [Abstract][Full Text] [Related]
34. "Idiopathic Eosinophilic Vasculitis": Another Side of Hypereosinophilic Syndrome? A Comprehensive Analysis of 117 Cases in Asthma-Free Patients.
Lefèvre G; Leurs A; Gibier JB; Copin MC; Staumont-Sallé D; Dezoteux F; Chenivesse C; Lopez B; Terriou L; Hachulla E; Launay D; Etienne N; Labalette M; DeGroote P; Pontana F; Quemeneur T; Hatron PY; Schleinitz N; Viallard JF; Hamidou M; Martin T; Morati-Hafsaoui C; Groh M; Lambert M; Kahn JE;
J Allergy Clin Immunol Pract; 2020 Apr; 8(4):1329-1340.e3. PubMed ID: 31863912
[TBL] [Abstract][Full Text] [Related]
35. Eosinophilia Induced by Blocking the IL-4/IL-13 Pathway: Potential Mechanisms and Clinical Outcomes.
Olaguibel JM; Sastre J; Rodríguez JM; Del Pozo V
J Investig Allergol Clin Immunol; 2022 Jun; 32(3):165-180. PubMed ID: 35522053
[TBL] [Abstract][Full Text] [Related]
36. Highlights of eosinophilic chronic rhinosinusitis with nasal polyps in definition, prognosis, and advancement.
Lou H; Zhang N; Bachert C; Zhang L
Int Forum Allergy Rhinol; 2018 Nov; 8(11):1218-1225. PubMed ID: 30296011
[TBL] [Abstract][Full Text] [Related]
37. Clinical and Biological Markers in Hypereosinophilic Syndromes.
Khoury P; Makiya M; Klion AD
Front Med (Lausanne); 2017; 4():240. PubMed ID: 29312946
[TBL] [Abstract][Full Text] [Related]
38. New-onset of eosinophilic granulomatosis with polyangiitis without eosinophilia and eosinophilic infiltration under benralizumab treatment: A case report.
Yonezawa H; Ohmura SI; Ohkubo Y; Otsuki Y; Miyamoto T
Mod Rheumatol Case Rep; 2023 Dec; 8(1):145-149. PubMed ID: 37243733
[TBL] [Abstract][Full Text] [Related]
39. Pharmacological profile of mepolizumab.
Pauk N
Vnitr Lek; 2023; 69(5):322-328. PubMed ID: 37827831
[TBL] [Abstract][Full Text] [Related]
40. A Rare Geriatric Diagnosis of Eosinophilic Granulomatosis With Polyangiitis: A Case Report.
Emidio FC; Pereira RC; Martins FR; Marques RC; Martins T
Cureus; 2023 Feb; 15(2):e35398. PubMed ID: 36846640
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
